Impact of bevacizumab administered dose on overall survival of patients with progressive glioblastoma

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial

(2014) Walter Taal et al.   LANCET ONCOLOGY

Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy

(2014) David E. Piccioni et al.   NEURO-ONCOLOGY

Use of Chemotherapy Within the Last 14 Days of Life in Patients Treated at a Comprehensive Cancer Center

(2014) Maria Alma Rodriguez et al.   JAMA Internal Medicine

Bevacizumab for radiation necrosis following treatment of high grade glioma: a systematic review of the literature

(2013) Daniel Lubelski et al.   JOURNAL OF NEURO-ONCOLOGY

A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas

(2010) Jeffrey J. Raizer et al.   CANCER

Randomized Double-Blind Placebo-Controlled Trial of Bevacizumab Therapy for Radiation Necrosis of the Central Nervous System

(2010) Victor A. Levin et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Bevacizumab and Recurrent Malignant Gliomas: A European Perspective

(2010) Wolfgang Wick et al.   JOURNAL OF CLINICAL ONCOLOGY

Pseudoprogression and pseudoresponse: Challenges in brain tumor imaging

(2009) Jennifer L. Clarke et al.   Current Neurology and Neuroscience Reports

Pseudoprogression and pseudoresponse in the treatment of gliomas

(2009) Dieta Brandsma et al.   CURRENT OPINION IN NEUROLOGY

Bevacizumab as Therapy for Radiation Necrosis in Four Children With Pontine Gliomas

(2009) Arthur K. Liu et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis

(2009) Roy Torcuator et al.   JOURNAL OF NEURO-ONCOLOGY

FDA Drug Approval Summary: Bevacizumab (Avastin(R)) as Treatment of Recurrent Glioblastoma Multiforme

(2009) M. H. Cohen et al.   ONCOLOGIST

Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations

(2009) Cristo Chaskis et al.   SURGICAL NEUROLOGY

Clinical pharmacokinetics of bevacizumab in patients with solid tumors

(2008) Jian-Feng Lu et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas

(2008) A. Desjardins et al.   CLINICAL CANCER RESEARCH

Bevacizumab Reverses Cerebral Radiation Necrosis

(2008) Eric T. Wong et al.   JOURNAL OF CLINICAL ONCOLOGY

Pseudoprogression in Glioblastoma

(2008) Marc C. Chamberlain   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

(2008) Teri N. Kreisl et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas

(2008) Dieta Brandsma et al.   LANCET ONCOLOGY

Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: Pitfalls in neurooncology

(2008) Alba A. Brandes et al.   NEURO-ONCOLOGY